GlassScriptPhysician profile
Michael H Moghimi
NPI 1063640001
$45,639.76
in general payments reported to CMS, 2019-2025
25 companies · $13K in 2025
The $13K reported for 2025 was more than what 89% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,087 · 2020: $638 · 2021: $778 · 2022: $1,200 · 2023: $1,574 · 2024: $23K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $20K · Travel and Lodging: $12K · Food and Beverage: $6,137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $19,750.00 |
| Travel and Lodging | $12,049.54 |
| Food and Beverage | $6,136.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spineart USA INC | $31,654.64 | 2020-2025 | Perla Tl, Juliet Ll, Perla Tl |
| Abbott Laboratories | $3,595.11 | 2019-2025 | Proclaim, Penta, Octrode |
| Intrinsic Therapeutics | $3,200.70 | 2025 | Barricaid Acd (Annular Closure Device) |
| Ctl Medical Corporation | $2,590.61 | 2019-2021 | |
| Si-Bone, INC. | $2,456.75 | 2019-2022 | |
| Cerapedics INC. | $545.71 | 2022-2025 | I-Factor Peptide Enhanced Bone Graft |
| Spineart Sa | $326.24 | 2024 | |
| Depuy Synthes Sales INC. | $230.30 | 2020-2021 | |
| Stryker Corporation | $199.84 | 2019-2021 | |
| Gs Solutions, INC. | $154.99 | 2024 | |
| Nuvasive, INC. | $148.91 | 2019 | |
| Medtronic, INC. | $133.69 | 2022 | |
| Orthofix Medical, INC. | $119.65 | 2019 | |
| Osteocentric Technologies, INC. | $52.52 | 2023 | Osteocentric 4.0 X 130mm Locking Bone Screw Fastener St |
| Alafair Biosciences, INC. | $38.42 | 2025 | Versawrap |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $29.55 | 2021 | |
| Bioventus LLC | $28.90 | 2019 | |
| Integra Lifesciences Corporation | $25.71 | 2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Orthogenrx INC. | $21.70 | 2019 | |
| Olympus America INC. | $19.80 | 2023 | |
| Pacira Pharmaceuticals Incorporated | $19.28 | 2019 | |
| Heron Therapeutics, INC. | $16.25 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $15.64 | 2019 | |
| Davol INC. | $14.85 | 2023 | Arista Ah Flexitip |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Moghimi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.